» Articles » PMID: 35719835

Prognostic Properties of the Association Between the S-100B Protein Levels and the Mean Cerebral Blood Flow Velocity in Patients Diagnosed with Severe Traumatic Brain Injury

Overview
Journal Biomed Rep
Specialty Biochemistry
Date 2022 Jun 20
PMID 35719835
Authors
Affiliations
Soon will be listed here.
Abstract

Craniocerebral injury (CBI) is tissue damage caused by a sudden mechanical force. CBI can result in neurological, neuropsychological and psychiatric dysfunctions. Currently, the severity of CBI is assessed using the Glasgow Coma Scale, brain perfusion pressure measurements, transcranial Doppler tests and biochemical markers. This study aimed to determine the applicability of the S-100B protein levels and the time-averaged mean maximum cerebral blood flow velocity (V) as a means of predicting the treatment outcomes of CBI in the first 4 days of hospitalization. The results validated the standard reference ranges previously proposed for the concentration of S-100B (0.05-0.23 µg/l) and the mean of cerebral blood flow velocity (30.9 to 74.1 cm/sec). The following stratification scheme was used to predict the success of treatment: Patients with a Glasgow Outcome Scale (GOS) score ≥4 or GOS <4 were stratified into 'favorable' and 'unfavorable' groups, respectively. The favorable group showed relatively constant levels of the S-100B protein close to the normal range and exhibited an increase in V, but this was still within the normal range. The unfavorable group exhibited a high level of S-100B protein and increased V outside of the normal ranges. The changes in the levels of S-100B in the unfavorable and favorable groups were -0.03 and -0.006 mg/l/h, respectively. Furthermore, the rate of decrease in the V value in the unfavorable and favorable groups were -0.26 and -0.18 cm/sec/h, respectively. This study showed that constant levels of S-100B protein, even slightly above the normal range, associated with an increase in V was indicative of a positive therapeutic outcome. However, additional research is required to obtain the appropriate statistical strength required for clinical practice.

Citing Articles

Cerebrospinal Fluid and Blood Biomarkers in Patients with Post-Traumatic Disorders of Consciousness: A Scoping Review.

Bagnato S, Boccagni C Brain Sci. 2023; 13(2).

PMID: 36831907 PMC: 9954419. DOI: 10.3390/brainsci13020364.

References
1.
Jennett B, Bond M . Assessment of outcome after severe brain damage. Lancet. 1975; 1(7905):480-4. DOI: 10.1016/s0140-6736(75)92830-5. View

2.
Pelinka L, Toegel E, Mauritz W, Redl H . Serum S 100 B: a marker of brain damage in traumatic brain injury with and without multiple trauma. Shock. 2003; 19(3):195-200. DOI: 10.1097/00024382-200303000-00001. View

3.
Goyal A, Failla M, Niyonkuru C, Amin K, Fabio A, Berger R . S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury. J Neurotrauma. 2012; 30(11):946-57. PMC: 3684103. DOI: 10.1089/neu.2012.2579. View

4.
Dadas A, Washington J, Diaz-Arrastia R, Janigro D . Biomarkers in traumatic brain injury (TBI): a review. Neuropsychiatr Dis Treat. 2018; 14:2989-3000. PMC: 6231511. DOI: 10.2147/NDT.S125620. View

5.
Tsivgoulis G, Alexandrov A, Sloan M . Advances in transcranial Doppler ultrasonography. Curr Neurol Neurosci Rep. 2008; 9(1):46-54. DOI: 10.1007/s11910-009-0008-7. View